Travere Therapeutics drug, approved for one rare and deadly kidney disease, fails in study of another
SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a rare …
Read More